Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Hikma Pharma Buys Stake in Hubei Haosun Pharma

publication date: Jul 11, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hikma Pharma, a Jordanian pharma with significant presence in the Middle East/North African region, paid $5 million to acquire a significant minority interest in Hubei Haosun Pharma. Haosun, which is privately held, develops and manufacturers difficult-to-make APIs with a specialization in oncology treatments. Hikma positioned the transaction as a means of gaining long-term access to high quality APIs. More details....     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors